Novo Nordisk

Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.

Beta Bionics is a biotechnology company based in Boston, Massachusetts, focused on advancing diabetes care through its innovative bionic pancreas system, known as the iLet. Founded in 2015, the company has developed a dual-chamber infusion pump that precisely delivers insulin and glucagon, allowing for autonomous management of blood sugar levels. The iLet has received breakthrough designation for its various configurations, including insulin-only, glucagon-only, and bihormonal uses, particularly in conjunction with Zealand Pharma’s dasiglucagon, a stable glucagon analog in a ready-to-use solution. By reducing the burden and cost associated with diabetes management, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Glooko is a comprehensive diabetes management platform designed to enhance health outcomes for individuals with diabetes and their healthcare teams. It connects with various diabetes devices and fitness trackers to gather essential data, including glucose levels, food intake, insulin usage, medications, blood pressure, diet, and weight. The platform is utilized in over 7,000 clinical locations and serves more than 1.5 million people with diabetes across 23 countries and in 15 languages. Glooko aims to facilitate remote patient monitoring by providing healthcare providers with valuable insights and analytics, ultimately supporting interventions that improve patient care and promote healthier behaviors.

Emisphere Technologies, Inc. is a pharmaceutical and drug delivery company based in Roseland, New Jersey, that utilizes its proprietary Eligen Technology to develop oral formulations of therapeutic agents. The company offers Eligen B12, an oral formulation designed for individuals with vitamin B12 deficiency. Emisphere is actively developing other products, including a GLP-1 formulation currently in Phase III clinical trials for the treatment of type 2 diabetes and related conditions. Additionally, the company engages in preclinical research focused on oral formulations for various medical needs, including diabetes, cardiovascular issues, appetite suppression, and pain management. Emisphere has established partnerships with global pharmaceutical companies to commercialize these innovations, including licensing agreements with Novo Nordisk for the development of oral formulations of GLP-1 receptor agonists and insulin. Founded in 1986, Emisphere Technologies transitioned to its current name in 1991 and operates as a subsidiary of Novo Nordisk as of December 2020.

Sundew ApS is a biotechnology company based in Copenhagen, Denmark, that specializes in developing biology-based technology platforms for addressing aquatic pests and diseases. Founded in 2018, Sundew utilizes precision fermentation to create products that meet the needs of the aquaculture market while providing environmentally-friendly solutions to ecological challenges, such as red tides and invasive species. The company focuses on delivering biologically-based services that are environmentally benign, climate-friendly, and cost-effective, enabling clients to effectively manage aquatic health issues.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing precision therapies for cardiovascular and renal conditions. Established in 2014, the company operates as a subsidiary of Novo Nordisk A/S. Corvidia specializes in researching and commercializing innovative treatments for chronic kidney disease, atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. By identifying patients with unique sensitivities to specific biological pathways, Corvidia aims to advance the development of transformative therapies that address the complex interplay between cardiovascular and renal health.

Beta Bionics is a biotechnology company based in Boston, Massachusetts, focused on advancing diabetes care through its innovative bionic pancreas system, known as the iLet. Founded in 2015, the company has developed a dual-chamber infusion pump that precisely delivers insulin and glucagon, allowing for autonomous management of blood sugar levels. The iLet has received breakthrough designation for its various configurations, including insulin-only, glucagon-only, and bihormonal uses, particularly in conjunction with Zealand Pharma’s dasiglucagon, a stable glucagon analog in a ready-to-use solution. By reducing the burden and cost associated with diabetes management, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Ziylo Ltd, founded in 2014 and based in Bristol, United Kingdom, specializes in developing glucose binding molecules (GBMs) aimed at improving the lives of individuals with diabetes. The company has pioneered a third class of GBMs, known as biomimetic molecules, which are essential for medical devices like Continuous Glucose Monitors (CGMs) and therapeutics such as Glucose Responsive Insulins (GRIs). This innovative platform is grounded in over 20 years of research conducted by Professor Anthony Davis at the University of Bristol, who is recognized for his contributions to the field of synthetic lectins—molecules that mimic natural carbohydrate-binding proteins. Ziylo's advancements in supramolecular chemistry aim to enhance glycemic control and ultimately help people with diabetes lead more normal and healthier lives. As of August 2018, Ziylo operates as a subsidiary of Novo Nordisk A/S.

IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.

Beta Bionics is a biotechnology company based in Boston, Massachusetts, focused on advancing diabetes care through its innovative bionic pancreas system, known as the iLet. Founded in 2015, the company has developed a dual-chamber infusion pump that precisely delivers insulin and glucagon, allowing for autonomous management of blood sugar levels. The iLet has received breakthrough designation for its various configurations, including insulin-only, glucagon-only, and bihormonal uses, particularly in conjunction with Zealand Pharma’s dasiglucagon, a stable glucagon analog in a ready-to-use solution. By reducing the burden and cost associated with diabetes management, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

MB2 operates in the healthcare industry that focuses on pharmaceutical businesses. It specializes in the fields of therapeutics, healthcare, and pharmaceuticals. MB2 is a U.S.-based company that was founded in 2014. The company was acquired by Novo Nordisk on August 27, 2015.

Calibrium is an emerging privately held biopharmaceutical company focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases. Calibrium was co-founded by Fritz French, Calibrium’s Chief Executive Officer, and Richard DiMarchi, PhD, Calibirum’s Chief Scientific Officer.

Xellia Pharmaceuticals ApS is a specialty pharmaceutical company based in Copenhagen, Denmark, dedicated to the development, manufacture, and supply of anti-infective products. The company specializes in fermented and semi-synthetic active pharmaceutical ingredients (APIs) and finished dosage forms, primarily targeting serious and life-threatening infections, including antibiotic-resistant bacterial and certain fungal diseases. Xellia is a leading supplier of Vancomycin and Colistimethate Sodium, with sales reaching over 700 customers across more than 70 countries. The company offers comprehensive contract manufacturing services, ranging from custom synthesis for clinical trials to large-scale production, along with stability testing, filling, and packaging of both dry powder and freeze-dried vials. Xellia operates four state-of-the-art manufacturing facilities located in Hungary, China, and the United States, all compliant with current Good Manufacturing Practices and approved by relevant regulatory authorities. With over 850 employees, Xellia continues to innovate and expand its product range to meet the evolving needs of the pharmaceutical industry.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Osprey Pharmaceuticals USA, Inc. is a clinical-stage biotechnology company based in San Francisco, California, that specializes in developing protein therapeutics aimed at treating inflammatory and immune diseases. Founded in 2008, the company focuses on a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs). These therapeutics are designed to selectively target and neutralize chemokine-activated leukocytes, which play a crucial role in various inflammatory conditions. Osprey's lead candidate, CCL2-LPM, specifically targets the CCR2 chemokine receptor found on pathologically activated leukocytes and is currently undergoing a Phase Ib clinical trial for the treatment of IgA nephropathy, an inflammatory kidney disease.

Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on discovering and developing anticalin-based therapeutics. Anticalins are low molecular-weight proteins derived from lipocalins, which are naturally occurring proteins in the human body. The company’s lead respiratory candidate, PRS-060, is in Phase I trials for asthma and other inflammatory diseases, while its lead immuno-oncology candidate, PRS-343, is also in Phase I trials targeting various cancers. Additionally, Pieris is advancing PRS-080, a treatment for functional iron deficiency in patients with chronic kidney disease, currently in Phase IIa trials, and PRS-344, a bispecific anticalin-antibody fusion protein in preclinical development for oncology. The company collaborates with several partners, including Les Laboratoires Servier, AstraZeneca, and Seattle Genetics, and has research collaborations with academic institutions such as the University of Pittsburgh. Founded in 2000, Pieris Pharmaceuticals aims to address critical medical needs through its innovative drug development approach.

Xencor, Inc. is a clinical-stage biopharmaceutical company based in Monrovia, California, specializing in the discovery and development of engineered monoclonal antibody and protein therapeutics aimed at addressing severe and life-threatening diseases. The company leverages its XmAb technology platform to create a diverse array of antibody product candidates, including XmAb5871 and XmAb7195 for autoimmune diseases, and XmAb14045, currently in Phase I clinical trials for acute myeloid leukemia. Other candidates in development target various cancers and include plamotamab for B-cell malignancies and XmAb18087 for neuroendocrine tumors. Xencor also collaborates with notable organizations in the biotechnology field to enhance its research and development efforts, generating revenue through these partnerships and licensing agreements. Founded in 1997, Xencor continues to advance its innovative therapeutics to meet significant unmet medical needs.

Innate Pharma S.A. is a clinical-stage biotechnology company based in Marseille, France, focused on developing therapeutic antibodies for oncology and inflammatory diseases. The company specializes in immunotherapies that leverage the innate immune system, particularly through its proprietary ANKET platform, which facilitates the creation of novel monoclonal antibodies. Innate Pharma's product pipeline includes several candidates in various stages of clinical development, such as Monalizumab, an immune checkpoint inhibitor for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody for cutaneous T-cell lymphoma. Other notable candidates include Avdoralimab, a therapeutic antibody targeting C5a receptors, and IPH5201, which aims to block the CD39 immunosuppressive pathway. Additionally, the company has formed strategic collaborations and licensing agreements with major pharmaceutical firms, enhancing its research capabilities and market reach. Founded in 1999, Innate Pharma continues to advance its innovative approaches to cancer treatment.

Aldaph SpA manufactures, packages, and markets pharmaceutical products.

TransTech Pharma, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of human therapeutics. The company engages in translating human proteins into medicines for the treatment of various human diseases. Its products include a pipeline of molecule clinical and pre-clinical drug candidates, including antagonists, fusion proteins, activators, inhibitors, agonists, smallpox anti-virals, and thrombosis for the treatment of cardiovascular disorders, central nervous system disorders, inflammatory and infectious diseases, diabetes, obesity, and cancer. TransTech Pharma, Inc. has strategic alliances with Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Merck, Siga Technologies, and Cephalon. The company was founded in 1998 and is based in High Point, North Carolina.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.